DNA Repair Drugs Market is expected to exhibit a CAGR of 32.4% Major Players Analysis GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc

DNA repair drugs are widely utilized for repairing damaged DNA, as well as for treating various types of cancer. DNA damage results usually in genetic disorders; however, the human body has its own mechanisms to correct the DNA sequence. DNA repair drugs, such as PARP inhibitors and other DNA repair drugs, help in the treatment of diseases with genetic aberrations.

The global DNA repair drugs market was evaluated at US$ 461.3 million in 2017, and is anticipated to exhibit a whopping 32.4% CAGR over the forecast period (2018-2026).]

Global DNA Repair Drugs Market Overview

Increasing incidence of cancer, rising government initiatives to promote awareness for cancer treatment, and expansion strategies being formulated by leading manufacturers to increase and expand their product portfolio in the international markets, are significant factors propelling the growth of the global DNA repair drugs market.

Request for a Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/2617

According to the World Cancer Research Fund International’s report in 2018, breast cancer accounted for the second highest number of cancer cases (2,088,849 new cases) across the globe in 2018. According to GLOBOCAN, 43.6% new cases of breast cancer were registered in Asia Pacific in 2018. Moreover, increasing drug approvals, which are helping address the rising demand for efficient therapeutics, is expected to further propel the global market development in the near future. For instance, in October 2018, Pfizer Inc. received the U.S. Food and Drug Administration (FDA) approval for Talazoparib (Talzenna) for treating patients with HER2 (negative locally advanced or metastatic breast cancer).

However, delay in receiving regulatory approvals result in the delayed marketing of the product, which could adversely affect the revenue generation for the manufacturers. Similarly, delay in post approval of the drug product for other therapeutic indication results in increasing clinical trials costs and can impact the labelling and approval status of currently marketed products.

Global DNA Repair Drugs Market – Geographical Landscape

North America is expected to dominate the global DNA repair drugs market over the forecast period, owing to increasing incidence of cancer. According to the American Cancer Society, in 2018, an estimated 266,120 new cases of invasive breast cancer were diagnosed in the U.S. Moreover, increasing demand for cancer treatments is expected to drive growth of the DNA repair drugs market in the region.

Request Here PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2617

Major Players Are Operating In This Market Are: AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc., Repare Therapeutics Inc., Karyopharm Therapeutics Inc., Ono Pharmaceutical Co., LTD., and Jiangsu Hengrui Medicine Co., Ltd.

Highlights of the DNA Repair Drugs report:

1. A complete backdrop analysis, which includes an assessment of the DNA Repair Drugs Market
2. An objective assessment of the trajectory of the market
3. Market segmentation up to the second or third level
4. Reporting and evaluation of recent industry developments
5. Important changes in market dynamics
6. Emerging niche segments and regional markets
7. Historical, current, and projected size of the market from the standpoint of both value and volume
8. Market shares and strategies of key players
9. Recommendations to companies for strengthening their foothold in the market

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.